

## State Corporation Commission 2007 Fiscal Impact Statement

**1. Bill Number** SB991

**House of Origin**    ☒ Introduced    ☐ Substitute    ☐ Engrossed

**Second House**    ☐ In Committee    ☐ Substitute    ☐ Enrolled

**2. Patron**        Blevins

**3. Committee**    Commerce and Labor

**4. Title**            Health insurance; coverage for bone marrow transplants.

**5. Summary/Purpose:** Repeals the requirement that insurers offer and make available coverage for dose-intensive chemotherapy/autologous bone marrow transplants and stem cell transplants for the treatment of breast cancer. The proposed amendment removes dose intensive chemo/ABMT, leaving stem cell transplants.

**6. No Fiscal Impact on the State Corporation Commission**

**7. Budget amendment necessary:** No

**8. Fiscal implications:** None on the State Corporation Commission

**9. Specific agency or political subdivisions affected:** State Corporation Commission Bureau of Insurance

**10. Technical amendment necessary:** No

**11. Other comments:** The Special Advisory Commission on Mandated Health Insurance Benefits has heard testimony suggesting that the dose intensive chemo/ABMT treatments are no longer used for the treatment of breast cancer. The issue of ABMT/stem cell transplants has been reviewed by the Special Advisory Commission twice. In 1994, The Special Advisory Commission recommended that a coverage mandate for ABMT/stem cell transplants should be enacted.

Senate Bill 991 should be referred to the Special Advisory Commission for review.

House Bill 2426 is similar to SB 991, but calls for the repeal of dose intensive chemo/ABMT and stem cell transplants.

The bill was passed by in committee with a letter on January 15.

**Date:** 01/15 /07 / V. Tompkins

cc: Secretary of Health and Human Resources  
Secretary of Commerce and Trade

